Tianjin Ringpu Bio-Technology Co Ltd banner
T

Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119

Watchlist Manager
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Watchlist
Price: 18.94 CNY -0.89%
Market Cap: ¥8.8B

Relative Value

The Relative Value of one Tianjin Ringpu Bio-Technology Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 18.94 CNY, Tianjin Ringpu Bio-Technology Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Tianjin Ringpu Bio-Technology Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Tianjin Ringpu Bio-Technology Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
8.8B CNY 2.3 21 18.3 18.3
US
Eli Lilly and Co
NYSE:LLY
961.6B USD 14.8 46.6 31.4 33.4
US
Johnson & Johnson
NYSE:JNJ
588.7B USD 6.2 22 15.2 18.7
CH
Roche Holding AG
SIX:ROG
295B CHF 4.8 31.4 13.2 15.4
UK
AstraZeneca PLC
LSE:AZN
242.6B GBP 5.6 32.3 17.8 25.1
CH
Novartis AG
SIX:NOVN
248.1B CHF 5.7 22.8 14 18
US
Merck & Co Inc
NYSE:MRK
301.6B USD 4.6 16.5 10.3 12.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.4 9.8 11.5
US
Pfizer Inc
NYSE:PFE
155.7B USD 2.5 20 7.5 10
UK
GlaxoSmithKline PLC
LSE:GSK
92.5B GBP 2.8 16.2 8.1 11.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
T
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Average EV/EBITDA: 43.5
18.3
38%
0.5
US
Eli Lilly and Co
NYSE:LLY
31.4
18%
1.7
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.2
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.8
11%
1.6
CH
Novartis AG
SIX:NOVN
14
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
8.1
2%
4.1